Will Recro Pharma Inc. (NASDAQ:REPH) Stock Recover After The Recent Fall?
Recro Pharma Inc. (NASDAQ:REPH) is down 10% in a month. The company has appointed Erica Raether as its maiden VP of people, culture, and ESG. Erica has over 20 years of experience in human resources in the medical devices and biotech sectors focused on developing and executing innovative strategies driving employee engagement, advancing ESGH goals, and attaining operational goals.
Recro President David Enloe said that the company has a commitment to its people and culture as well as ESG, and it was natural to create the VP people, culture, and ESG role. As a result, it befitted an experienced individual, and Erica holds an impressive record in the area.
Recently, the company signed a development and cGMP manufacturing deal with a new customer to offer early-stage development and production services. In addition, the company will support the customer’s clinical development that is in the progress of an orally delivered and minimally-absorbed experimental compound. So in the coming months, REPH is a stock to watch.
Market Reaction:
On Tuesday, REPH stock leaped 4% at $1.88 with more than 257k shares, compared to its average volume of 545k shares. The stock has moved within a range of $1.7900 – 1.9000 after opening the trade at $1.80. Over the past 52-week, the stock has been trading within a range of $1.4900 – 5.2900.
